1. 041 Serum Metabolomic Analysis Identifies Unique Signatures in Azoospermic Men. (1st July 2018) Authors: Zhang, Z.; Yang, Y.; Jiang, H. Journal: Journal of sexual medicine Issue: Volume 15(2018)Supplement 3 Page Start: S141 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 045 The Fertility Quality of Life and Sexual Dysfunction in Men Seeking Fertility Treatment. (1st July 2018) Authors: Zhang, Z.; Yang, Y.; Jiang, H. Journal: Journal of sexual medicine Issue: Volume 15(2018)Supplement 3 Page Start: S143 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 106P Zanubrutinib in combination with tislelizumab in patients with refractory diffuse large B cell lymphoma (DLBCL): A phase II study. (December 2022) Authors: L. Zuo, ; Zhou, S.; Liu, P.; Yang, S.; Yang, J.; He, X.; Gui, L.; Li, R.; Yang, Y. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 129P Tislelizumab combined with bevacizumab plus nab-paclitaxel single-agent chemotherapy for advanced NSCLC after resistance to EGFR TKIs. (December 2022) Authors: Zhou, C.; Xie, X.; Yang, Y.; Lin, X.; Xie, Z.; Zhou, M.; Qin, Y.; Zhang, J. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 140P Patient-reported outcomes (PRO) following sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous NSCLC: A randomized, double-blind, phase III study (Orient-12). (December 2022) Authors: Zhou, C.; Gao, G.; Fan, Y.; Liu, L.; Zhang, L.; Cang, S.; Zhou, J.; Li, B.; Yang, Y.; Li, J. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 144P Toripalimab plus chemotherapy as neoadjuvant treatment for resectable stage IIB-IIIB NSCLC (RENAISSANCE study): A single-arm, phase II trial. (December 2022) Authors: Yan, S.; Wang, J.; Lyu, C.; Bi, J.; Xin, Y.; Liu, B.; Li, S.; Wang, Y.; Chen, J.; Li, X.; Yang, Y.; Wu, N. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 149P A phase Ⅰb/Ⅱ trial of surufatinib plus toripalimab and etoposide (E) combined with cisplatin (P) in patients (pts) with untreated advanced small cell lung cancer (SCLC). (December 2022) Authors: Fang, W.F.; Huang, Y.; Yang, Y.; Zhao, Y.; Zhang, Y.; Zhou, T.; Zhao, S.; Yuxiang, M.; Hong, S.D.; Zhao, H.; Zhang, L. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. 152P A phase I study of HBM4003, an anti-CTLA-4 heavy chain only monoclonal antibody, in combination with toripalimab in advanced melanoma. (December 2022) Authors: Bixia, T.; Chi, Z.; Chen, Y.; Jiang, Y.; Fang, M.; Gao, Q.; Huang, G.; Ren, X.; Yao, Y.; Chen, J.; Zhang, X.; Li, R.; Humphrey, G.; Ding, L.; Geng, Y.; Zhao, S.; Yang, Y.; Lu, Z.; Ye, D.; Guo, J. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. 1A.07: GENOME-WIDE PROFILING OF LONG NONCODING RNA EXPRESSION PATTERNS IN THORACIC AORTA FROM SPONTANEOUSLY HYPERTENSIVE RATS. (June 2015) Authors: Yu, J.; Cai, Y.; Liu, Y.; Yang, Y.; Chen, Y.; Jose, P.A.; Wang, D.; Zhou, L.; Zeng, C. Journal: Journal of hypertension Issue: Volume 33(2015)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. 1‐Watt highly linear HBT power amplifier driver integrated circuit with low current consumption. Issue 7 (26th April 2013) Authors: Joo, S.; Han, S.; Song, M.; Kim, H.; Ham, J.; Seo, M.; Kim, M.; Park, C.; Yang, Y. Journal: Microwave and optical technology letters Issue: Volume 55:Issue 7(2013:Jul.) Page Start: 1680 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗